The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Continuing Penalty Fee Cuts for Hospitals, Pharmacies with Revised Scope
December 7, 2015
- NHI-Market Price Gap of 8.8% Reported to Chuikyo; Generic Share at 56.2% in September
December 7, 2015
- MHLW Calls for 50% Pricing Rule for First Generics, 40% Rule for 10-Plus Oral Generics
December 4, 2015
- New HTA Scheme Should Only Cover Big-Selling Products Given Big Premiums: JPMA Chief
December 4, 2015
- Chuikyo Subcommittee Agrees on Scope of “Essential Drugs”; Trial Run of Innovation Premium to Continue
December 4, 2015
- Chuikyo Basically OKs 2-Tiered Re-Pricing for Huge Seller Drugs; Sovaldi Almost Certain to Face Cut
December 3, 2015
- Probe Finds Kaketsuken’s GMP Violations “Extremely Malicious”, MHLW to Impose Penalty
December 3, 2015
- NHI-Market Price Gap at 8.8%, 6.8% Price Cut Expected in FY2016 Revision
December 3, 2015
- Generic Replacement Rate Applied to Z2 Rule to Be Hiked 10%
December 3, 2015
- Revamped Sakigake Pricing Premium to Grant Maximum Premium Rate of 20%: Chuikyo Subcommittee
December 3, 2015
- Interstitial Pneumonia Added to ADR List for Daklinza, Sunvepra
December 2, 2015
- MHLW Discussing Use of Disease Registry as Substitute for Control Groups; Could Be “One Means of Evaluation” in Trials for Rare Diseases
December 2, 2015
- MHLW Study Group to Survey Unvaccinated Teens to Resolve HPV Issues
December 1, 2015
- PAFSC’s 2nd Committee Backs Lung Cancer Indication for Opdivo
December 1, 2015
- Development of Orphan Drugs Will Require Global Perspective: MHLW Official
December 1, 2015
- PAFSC 1st Committee Gives Nod to Japan’s First PCSK9 Inhibitor
November 30, 2015
- Evaluation of Efficacy Was Challenging in Sakigake Pick, Designating All Qualified Drugs Desirable: MHLW Official
November 27, 2015
- New Dosage Form of Ciproxan, Other Products with Minor Changes to Join NHI Price List on Nov. 28
November 27, 2015
- MHLW Allows Shipment of Kaketsuken DTP-IPV Vaccine
November 27, 2015
- Drug Pricing Debate to Culminate in December; Abraxane, Zosyn Major Candidates for Market Expansion Re-Pricing
November 26, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…